Drug Profile

Ubiquinol - Nobelpharma

Alternative Names: NPC-29

Latest Information Update: 06 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nobelpharma
Class Alcohols; Antineoplastics; Benzoquinones; Cardiotonics; Coenzymes; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

30 Sep 2025 Nobelpharma intends to file a marketing authorisation application for ubiquinol for multiple system atrophy in Japan in August 2029 (Nobelpharma pipeline, September 2025)
07 Aug 2024 Phase-II clinical trials in Multiple system atrophy in Japan (unspecified route) (Nobelpharma pipeline, August 2024)
07 Aug 2024 Nobelpharma plans a phase III trial for Multiple system atrophy in September 2024 (Nobelpharma pipeline, August 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com